Work

Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database

Year: 2021

Type: article

Study design: Observational Study

Source: Leukemia Research

DOI: 10.1016/j.leukres.2021.106629

Authors: Douglas Tremblay, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark Heaney, Andrew Kuykendall, Casey O’Connell, Jamile M. Shammo, Angela Fleischman, Ruben Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta, John Mascarenhas

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Hospital of the University of Pennsylvania, Yale University, Stanford Cancer Institute, Stanford University, Columbia University Irving Medical Center, Moffitt Cancer Center, University of Southern California, Rush University Medical Center, University of California, Irvine, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, University of Kansas, The University of Kansas Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3165639147

FWCI: 0.556

Cites: 26

Cited by: 7

Related to: 10